Lund, Sweden, 2015-05-12 11:23 CEST (GLOBE NEWSWIRE) --
The April issue of the German Urology journal Urologische Nachrichten, contained two articles relating to the use of the software EXINI bone BSI and BSI in quantification of tumour burden in patients suffering from skeletal metastatic prostate cancer (mCRPC).
T he articles: ”Quantifizierung der ossären Metastasierung bei mCRPC” (Quantification of Bone Metastases among mCRPC), written by Dr. Inga Peters and Prof. Georg Berding at the Medizinische Hochschule in Hannover, and ”Bone Scan Index bei mCRPC-Patienten” (Bone Scan Index among mCRPC-patients), written by Dr. Till Eichenauer and Dr. Lars Budaeus at the Martini Clinic, Hamburg University Hospital, both demonstrate the use for EXINI’s automated calculation of BSI-value in evaluating patients suffering from castration-resistant skeletal metastatic prostate cancer.
”In the future, automated calculation of BSI may provide us with more accurate definitions of progression, leading up better treatment decisions.” (Dr. Peters, Prof. Berding)
”Analysis shows that an increased BSI-value corresponds to an increased patient mortality. A corresponding increase of PSA-value, on the other hand, shows no significance.” (Dr. Erichenauer, Dr. Budaeus)
”Having EXINI bone BSI and BSI described in articles from two renowned university hospitals in an editorial journal, reaching the majority of urologists in Germany, is excellent,” says Magnus Aurell, CEO at EXINI Diagnostics AB.
More on Urologische Nachrichten: Urologische Nachrichten is an up-to-date, independent national monthly journal for urologists demonstrating editorial ambitions. It targets all German-speaking urologists in both public and private sector.
More on Bone Scan Index (BSI): BSI is an imaging biomarker providing fast, accurate and quantifiable information to be used for diagnosis and stratification and the monitoring of treatment response. It also provides increased accuracy in prognoses involving patients suffering from skeletal metastases originating from prostate cancer.
Moreover, BSI has demonstrated its importance in the process of developing new drugs, thus proving itself just as important for clinical use as for the pharmaceutical industry. EXINI bone BSI is the only software capable of calculating the BSI-value.
www.bonescanindex.org www.exini.com/software/exini-bone-bsi/
For more information, please contact: Magnus Aurell, CEO Phone: +46 46 286 54 25 E-mail: magnus.aurell@exini.com
About EXINI Diagnostics AB (publ) EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of medical images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as cancer, coronary heart disease, dementia and Parkinson's disease. EXINI is listed on the stock market NASDAQ OMX First North and has about 1000 shareholders. Consensus acts as Certified Adviser.
________________________________________________________________________ EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70 Lund, Sweden Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com
